The Patent Finder
IP

Inozyme Pharma, Inc.

First filing 2013
OverviewNotableFeesChangesPatent listSources & methods

0 patents currently held, every record listed here

6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

This portfolio holds none of the 6 US patents in force on its record. from the record

Of the 6 now held by other companies, 6 name Biomarin Pharmaceutical Inc. as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end

When these terms end

Each bar runs from grant to computed term end. 2014 to 2043.
US 8,846,603 NPP1 Fusion Proteins Mar 11, 2031
US 9,540,621 NPP1 Fusion Proteins no later than Mar 11, 2031
US RE49,529 Methods of Treating Tissue Calcification Dec 18, 2035
US 11,364,284 Methods of Treating Myointimal Proliferation Jan 18, 2039
US 12,134,790 Methods of Improving Cardiovascular Function and Treating Cardiovascular Disease Using a Recombinant Ectonucleotide Pyrophosphatase Phosphodiesterase (NPP1) May 29, 2039
US 12,698,487 Soluble ENPP1 Proteins and Uses Thereof Apr 28, 2043
20202026203220382043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
4 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 31 later US patents, top 25% of utility patents granted in 2014 in our data. Protection runs to 2031.
Ends Mar 2031 · High confidence
Also notable Ends Jan 2039 · High confidence
Also notable
Granted 2023. Computed term ends 2035.
Ends Dec 2035 · Low confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Also on record: 6 patents in force now held by others · 1 patent ended · 4 applications pending · 12 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 patents carry no fee events. That is a gap in the record, not evidence of lapse, so status falls back to the computed term
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
2 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited